HomeLatest NewsFederal NewsChanges to Prescribing Treatment of Opioid Use Disorder

Changes to Prescribing Treatment of Opioid Use Disorder

Effectively immediately, the federal requirement to have a waiver (DATA X-waiver/Notice of Intent) to prescribe medications for the treatment of opioid use disorder (OUD), such as buprenorphine is NO longer required, and prescribers are able to, and encouraged by the Substance Abuse and Mental Health Services Administration (SAMHSA), to prescribe buprenorphine in their practices as permitted by applicable state law.

Below is information taken from the Substance Abuse and Mental Health Services Administration (SAMHSA) announcement on their website located here:

“All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023.”

The South Dakota Division of Behavioral Health has information regarding contracted MAT/MOUD providers on avoidopioidsd.com, as well as other resources related to opioid prevention, treatment, and recovery resources. If you are looking for substance use disorder resources related to treatment services funded by the Division of the Behavioral Health, please visit the website at dss.sd.gov/behavioralhealth/services.

If your facility would like to learn more about ways to combat substance use disorder including helpful tools, please contact the SDAHO Team at 605-361-2281.

Stay Connected

Unified Voice Newsletter

Events This Month



08jun12:00 pm1:00 pmNursing Services Condition of ParticipationSDAHO Webinar

13jun12:00 pm1:00 pmAchieving Clinical Workforce Stability in the New NormalAHA Webinar

14jun10:00 am11:00 amThe Medicare "Must Knows" and Updates for Home HealthSDAHO Webinar

14jun12:00 pm1:00 pmBuprenorphine & its Efficacy for Patients with Serious Illness and End of Life Care SituationsSDAHO Webinar

By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact